Technical Analysis for MRUS - Merus N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 48.36 | 1.81% | 0.86 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 0.00% | |
| Cup with Handle | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Gapped Up (Full) | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Up 3% | 2 days ago |
| Up 2% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 52.035 |
| 52 Week Low | 18.85 |
| Average Volume | 631,966 |
| 200-Day Moving Average | 31.21 |
| 50-Day Moving Average | 45.13 |
| 20-Day Moving Average | 43.13 |
| 10-Day Moving Average | 44.61 |
| Average True Range | 1.99 |
| RSI (14) | 69.70 |
| ADX | 26.67 |
| +DI | 27.92 |
| -DI | 8.91 |
| Chandelier Exit (Long, 3 ATRs) | 43.54 |
| Chandelier Exit (Short, 3 ATRs) | 45.23 |
| Upper Bollinger Bands | 48.18 |
| Lower Bollinger Band | 38.07 |
| Percent B (%b) | 1.02 |
| BandWidth | 23.43 |
| MACD Line | 0.84 |
| MACD Signal Line | 0.02 |
| MACD Histogram | 0.8131 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.62 | ||||
| Resistance 3 (R3) | 50.75 | 50.13 | 50.25 | ||
| Resistance 2 (R2) | 50.13 | 49.55 | 50.06 | 50.12 | |
| Resistance 1 (R1) | 49.24 | 49.19 | 48.93 | 49.11 | 50.00 |
| Pivot Point | 48.62 | 48.62 | 48.46 | 48.55 | 48.62 |
| Support 1 (S1) | 47.73 | 48.04 | 47.42 | 47.61 | 46.72 |
| Support 2 (S2) | 47.11 | 47.68 | 47.04 | 46.60 | |
| Support 3 (S3) | 46.22 | 47.11 | 46.47 | ||
| Support 4 (S4) | 46.10 |
